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ABSTRACT 26 
Thyroid hormone is essential for normal human fetal growth and brain development. 27 
As the fetal thyroid does not secrete thyroid hormones until about 18 weeks gestation, 28 
early fetal brain development depends on passage of maternal hormone across the 29 
placenta into the fetal circulation. To reach the fetal brain, maternally derived and 30 
endogenously produced thyroid hormone has to cross the blood-brain and blood-31 
cerebrospinal fluid barriers. In this review we will discuss the complex biological 32 
barriers (involving membrane transporters, enzymes and distributor proteins) that 33 
must be overcome to ensure that the developing human brain has adequate exposure 34 
to thyroid hormone.  35 
 36 
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1. Introduction 51 
Thyroid hormones (TH) are essential for normal human fetal development and 52 
especially important in the development of the central nervous system. The 53 
hypothalamic-pituitary-thyroid (HPT) axis begins to develop at around 5 weeks 54 
gestation and while there is some TH synthesis at about 12 weeks, significant amounts 55 
of TH are not produced until after the 18th week of gestation. This means that the 56 
developing fetus requires an adequate and timely supply of TH from its mother 57 
through the placenta. In order to reach the developing fetal brain, TH in the fetal 58 
circulation then must traverse the blood-brain barrier (BBB) and the blood-59 
cerebrospinal fluid barrier (BCSFB). Each of these barriers (placental and brain) have 60 
unique structures comprised of cells that express different TH membrane transporters, 61 
metabolising enzymes and distributor proteins. 62 
1.1 Membrane transporters 63 
Due to the lipophilic nature of THs, it was historically believed that THs could 64 
passively traverse membranes. However, THs are charged and cannot cross a 65 
phospholipid bilayer (Schweizer and Kohrle, 2013). Over the last two decades several 66 
membrane transporters capable of transporting TH have been identified (see (Visser, 67 
2000, Visser et al., 2008, Visser et al., 2011)) including the organic anion transporting 68 
polypeptides OATP1A2, OATP4A1 and OATP1C1, the L-type amino acid 69 
transporters LAT1 and LAT2 (Friesema et al., 2001) and the more recently described 70 
specific TH transporter monocarboxylate transporters MCT8  and MCT10 (Friesema 71 
et al., 2003).  72 
1.2 Metabolising enzymes 73 
During vertebrate development, the action of TH is coordinated by three 74 
iodothyronine deiodinases: Type 1 (D1), Type 2 (D2) and Type 3 (D3), that differ in 75 
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substrate specificity and tissue distribution. D2 is an outer ring deiodinase that 76 
converts transcriptionally inactive thyroxine (T4) to active triiodothyronine (T3). 77 
Conversely D3 is an inner ring deiodinase that inactivates T3 to diiodothyronine (T2) 78 
or T4 to reverse triiodothyronine (rT3).  D1 has both inner and outer ring deiodinase 79 
activity. For a review on deiodinases see (Dentice and Salvatore, 2011). The balance 80 
of D2 and D3 activity plays an important role in fetal development by ensuring safe 81 
levels of TH are maintained (Richard K et al., 1998). 82 
In addition to deiodination, THs are metabolised by conjugation of the phenolic 83 
hydroxyl group with sulfate or glucuronic acid (Wu et al., 2005).  Sulfation and 84 
glucuronidation increase water-solubility of the substrates, which facilitates biliary 85 
and/or urinary clearance.  Sulfation of TH is catalysed by sulfotransferases and 86 
desulfation by arylsulfatases. TH sulfates are the preferred substrates for deiodination 87 
(Visser, 1994) and are rapidly degraded in liver by D1.  In the presence of low D1 88 
activity, T3 sulfate may function as a reservoir of inactive hormone from which active 89 
T3 may be recovered by arylsulfatases (Visser, 1994). Glucuronidation of TH is 90 
catalysed by UDP-glucuronyltransferases that utilise UDP-glucuronic acid as a 91 
cofactor.   Glucuronidation of TH appears to be more important in rodents than in 92 
humans (Visser et al., 1993). 93 
1.3 TH Distributor proteins 94 
In serum, TH is bound to three hepatically synthesised distributor proteins, which are, 95 
in order of their affinity for T4, thyroxine binding globulin (TBG), transthyretin 96 
(TTR) and albumin (Chopra, 1996). The extent of overall binding is great such that 97 
the free T4 concentration in serum is less than 0.1% of total T4.  TTR is also 98 
synthesised by several other cell types including placenta (McKinnon et al., 2005) and 99 
choroid plexus (Herbert et al., 1986) and plays a role in transporting TH into cells 100 
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(Landers et al., 2009, Landers et al., 2013, Schreiber et al., 1990). Several intracellular 101 
TH binding proteins have also been identified that may modify TH transport and 102 
access to nuclear TH receptors including alpha-1-antitrypsin, alpha-1-acid glycoprotein 103 
and mu-crystallin (Barsano and DeGroot, 1993, Barsano and DeGroot, 2012, 104 
McKinnon et al., 2005, Suzuki et al., 2007). 105 
2. The Placental Barrier 106 
2.1 Placental structure 107 
The human placenta is a highly specialised organ that actively exchanges nutrients 108 
and waste between the maternal and fetal circulations. During the first 10-12 weeks of 109 
gestation, the fetus is bathed in amniotic fluid and is completely surrounded by the 110 
placenta through which maternal-fetal exchange occurs (Gude et al., 2004).  During 111 
this time, the placenta is primarily made up of cytotrophoblasts, which undergo 112 
proliferation and differentiation into a multinucleated syncytium called the 113 
syncytiotrophoblast (Gude et al., 2004, Huppertz and Peeters, 2005) and transport of 114 
nutrients and waste between maternal and fetal circulations occurs across these two 115 
layers of cells (Gude et al., 2004). By the 13th week of pregnancy (Foidart et al., 1992) 116 
the hemochorial plate is formed allowing chorionic villi to be perfused by maternal 117 
blood (Huppertz and Peeters, 2005). At this time, the placental barrier consists of four 118 
layers, the maternal facing syncytiotrophoblasts, a layer of cytotrophoblasts, 119 
connective tissue and the endothelial cells lining the fetal capillaries.  The utero-120 
placental unit consists of the chorionic plate derived from the fetal chorionic sac and 121 
the basal plate derived from maternal endometrium.  In between these two regions is 122 
the intervillous space where chorionic villi are bathed in maternal blood introduced 123 
through maternal spiral arteries. The placental barrier is formed by the tight layer of 124 
multinucleated syncytiotrophoblasts, located on the chorionic villi that separate 125 
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maternal blood from fetal capillaries and is the layer of cells through which maternal-126 
fetal exchange occurs (Fig.1).  127 
2.2 Placental TH transport 128 
For many years it was thought that the placenta was impermeable to thyroid hormones 129 
(TH) despite early studies demonstrating that radiolabeled TH crossed the placenta 130 
(Fisher et al., 1964).  Later, the discovery of high D3 activity suggested that 131 
intracellular deiodination may provide the barrier to placental TH transport (Roti et 132 
al., 1981). However in 1989, Vulsma et al (Vulsma et al., 1989) demonstrated that 133 
fetuses unable to produce TH had significant (but low) circulating TH levels at birth 134 
providing evidence of materno-fetal transfer of TH.  135 
Since then the presence of both T3 and T4 have been identified in the fetal 136 
exocoelomic cavity and in fetal tissues from 5 weeks gestation although the fetal 137 
thyroid gland does not start to function until around 18 weeks gestation (Calvo et al., 138 
2002). Additionally in early pregnancy fetal brain T4 levels reflect maternal serum 139 
levels (Chan et al., 2009, Ferreiro et al., 1988).  140 
Transport of TH across the trophoblast cell membrane was first reported in 1992 141 
(Mitchell et al., 1992). Since then, six transporters have been identified in placental 142 
tissue; LAT1 (Ritchie and Taylor, 2001) and LAT2 (Park et al., 2005), OATP1A2 143 
(Patel et al., 2003) and OATP4A1 (Sato et al., 2003) and MCT8 (Chan et al., 2006) 144 
and MCT10 (Kim et al., 2001) (for a review see (Patel et al., 2011)). MCT8, MCT10, 145 
OATP1A2, OATP4A1 and LAT1 are all expressed in syncytiotrophoblasts while 146 
MCT8, MCT10 and OATP1A2 are expressed in cytotrophoblasts (Loubiere et al., 147 
2010). All of these transporters, with the exception of MCT8, also transport other 148 
ligands (Loubiere et al., 2010). The large numbers of placental TH transporters 149 
suggests some functional redundancy. 150 
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2.3 Placental metabolising enzymes 151 
Once the TH enters the trophoblast cell it is vulnerable to deiodination by D2 or the 152 
more highly expressed inactivating D3 (Koopdonk-Kool et al., 1996).  D2 is found in 153 
the villous cytotrophoblast in the first trimester and the syncytiotrophoblast in the 154 
third trimester whereas D3 is localised to the syncytiotrophoblasts in both the first and 155 
third trimesters (Chan et al., 2003).  D3 activity in human placenta is up to 400 times 156 
greater than that of D2 (Koopdonk-Kool et al., 1996) and, using the perfused human 157 
placenta it has been demonstrated that, unless D3 activity is inhibited, T4 cannot cross 158 
the placenta in significant amounts (Mortimer et al., 1996). 159 
Several sulfotransferase (SULT) enzymes are expressed in placenta, particularly those 160 
of the SULT1A family (Stanley et al., 2001). Despite this, very little THs sulfation 161 
occurs in human placenta (Stanley et al., 2001). 162 
2.4 Placental TH Distributor Proteins 163 
Human placenta synthesises several TH distributor proteins including transthyretin 164 
(TTR), albumin, α-1-antitrypsin and α-1-acid glycoprotein (McKinnon et al., 2005). 165 
The nonsteroidal antiinflammatory drug mefenamic acid is a potent inhibitor of T4 166 
protein binding and incubation of placental homogenates with mefenamic acid 167 
increases deiodination of T4, most probably because T4 displaced from TTR, 168 
albumin, and possibly other thyroid hormone binding proteins would be more 169 
available for deiodination (McKinnon et al., 2005). This strongly suggests that TTR 170 
and possibly other TH distributor proteins are involved in the safe transfer of TH from 171 
mother to fetus across the placenta (Landers et al., 2013). TTR produced by human 172 
placenta is mainly secreted across the apical membrane toward the maternal 173 
circulation (Mortimer et al., 2012).  TTR is also endocytosed through the apical 174 
membrane of trophoblasts and uptake is increased by TH binding (Landers et al., 175 
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2009). Uptake of the TTR-TH complex is through a receptor-mediated mechanism 176 
(Landers et al., 2013) and is greater in a low oxygen environment such as that found 177 
in first trimester placenta (Patel et al., 2010, Patel et al., 2012) when the requirement 178 
for maternal TH is at its highest. The receptor for the TTR-TH complex has not yet 179 
been identified but there is strong evidence that it is a member of the Lipoprotein 180 
Receptor Related Protein (LRP) family since uptake of TTR-TH is sensitive to the 181 
chaperone protein Receptor Associated protein (RAP) (Landers et al., 2013).  182 
Incubation of human placental explants with fluorescently labelled TTR results in 183 
accumulation of TTR in placental fetal capillaries (Mortimer et al., 2012) indicating 184 
TTR is capable of transplacental passage; whether or not it is in a complex with TH 185 
remains to be determined. 186 
2.5 Proposed model of TH transfer across placenta 187 
There is still much controversy surrounding the route of TH transfer across the 188 
placenta. Several TH transporters are expressed by trophoblasts suggesting there is 189 
some redundancy in the system; not surprising considering the importance of maternal 190 
TH for fetal development. Given the high levels of D3 in placenta (Koopdonk-Kool et 191 
al., 1996) and the protective effect of TTR binding (McKinnon et al., 2005), there is 192 
strong evidence that TTR may chaperone TH across the placental barrier to the fetal 193 
capillaries (Landers et al., 2013, Landers et al., 2009, McKinnon et al., 2005, 194 
Mortimer et al., 2012) (Fig.1). 195 
 196 
 197 
3. Brain 198 
Once in the fetal circulation, maternal THs must then traverse into the fetal brain. To 199 
do this they must cross the Blood-Brain Barrier (BBB), the Blood-Cerebrospinal Fluid 200 
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Barrier (BCSFB) or both (Fig.2). These barriers have two main functions; to impede 201 
free diffusion between blood and brain fluids and to provide transport processes for 202 
nutrients, ions and waste products (Redzic, 2011).  203 
In adult rodents, the BBB is the primary route for TH to enter the brain, with a smaller 204 
amount entering through the BCSFB (Dratman et al., 1991, Horn and Heuer, 2010). 205 
However, there is evidence that the choroid plexuses (BCSFB) are the main route of 206 
transfer from blood to brain in rat fetuses (Johansson et al., 2008). 207 
In 1954, Grontoft (Grontoft, 1954) demonstrated that dye injected into the blood 208 
stream did not enter the brain of human fetuses of 5 – 26cm long (approx. 10-20 209 
weeks gestation) suggesting a functional barrier exists very early in development. 210 
Additionally, some mechanisms present in embryos are not present in adults, e.g., 211 
specific transport of plasma proteins across the blood–CSF barrier (Dziegielewska et 212 
al., 1988) and embryo-specific intercellular junctions between neuroependymal cells 213 
lining the ventricles (Saunders et al., 2012). For an excellent review of human brain 214 
barrier mechanisms in developing brain see (Saunders et al., 2012). 215 
There is very little known about the route of TH entry to the developing human brain 216 
given the difficulty of conducting such studies, and much of our information is based 217 
on conjecture from work with developing rodents and studies of adult human brain.  218 
3.1 Blood-Brain Barrier 219 
The BBB separates circulating blood from brain interstitial fluid and is localised to 220 
the monolayer of endothelial cells lining brain capillaries (Fig. 2).  Brain endothelial 221 
cells have a specialised morphology in that they are connected to adjacent endothelial 222 
cells via tight junctions (Vorbrodt and Dobrogowska, 2003).  These tight junctions 223 
restrict the paracellular passage of compounds in both directions (Anderson and Van 224 
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Itallie, 2009, Wolburg and Lippoldt, 2002).  Astrocytic end feet that line the basal side 225 
of brain endothelial cells also provide a barrier function (Abbott et al., 2006).  226 
3.1.1 Thyroid hormone transporters in the BBB 227 
A number of thyroid hormone transporters have been identified in brain with species-228 
specific expression and distribution (for a comprehensive review see (Wirth et al., 229 
2014)).  In both fetal and adult humans and adult rodents, MCT8 is expressed in 230 
cerebral micro-vessels and in neurons (Roberts et al., 2008).  In micro-vessels MCT8 231 
is localised predominantly to the luminal (blood-facing) surface.  OATP1C1 is also 232 
expressed in cerebral micro-vessels of adult rodents and both fetal and adult humans, 233 
however OATP1C1 in humans is present at comparatively lower levels (Roberts et al., 234 
2008).  OATP1C1 in micro-vessels is localised mainly to the abluminal (brain-facing) 235 
surface with some staining overlapping with aquaporin 4, a marker of astrocytic end 236 
feet (Roberts et al., 2008). 237 
In MCT8 deficient mice, T4 is still transported to the brain, however mice deficient in 238 
both MCT8 and OATP1C1 have diminished concentrations of T3 and T4 in brain 239 
(Mayerl et al., 2014). The difference in OATP1C1 expression between species is most 240 
likely the reason that human males with MCT8 mutations present with a severe X-241 
linked neurological condition (Allan-Herndon-Dudley Syndrome), whilst Mct8 null 242 
mice exhibit a normal neurological phenotype (Kersseboom and Visser, 2011, 243 
Kersseboom and Visser, 2011). 244 
LAT1 and LAT2 are both expressed in mouse neuron and astrocytic cells and both 245 
transporters have been shown to be involved in T3 and T4 uptake into neurons and 246 
astrocytes (Braun et al., 2011, Wirth et al., 2009).  LAT2 is present in mouse neurons 247 
at all stages of development; however, there is no expression of LAT2 in developing 248 
neurons of humans (Braun et al., 2011, Wirth et al., 2009).  LAT1 and to a lesser 249 
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extent LAT2 are detected in human brain capillary endothelial cells (de Boer et al., 250 
2003, Muller and Heuer, 2014).  251 
3.1.2 TH metabolising enzymes in the BBB 252 
In humans, D2 is present in the cerebral cortex during the first trimester of 253 
development. T3 can also be detected in first trimester brain (Chan et al., 2002). D2 is 254 
found almost exclusively in glial cells including the astrocytes (Guadano-Ferraz et al., 255 
1997) that line the brain endothelial cells and provide part of the barrier function. D2 256 
expression in fetal rat brain increases between gestational days 19 and 21 and 257 
increases in response to low serum T4 levels (Ruiz de Ona et al., 1988). Neurons are 258 
the only type of brain cell to demonstrate D3 expression in both mice and humans 259 
(Galton, 2005) and human fetal cerebellum has high D3 activity (Kester et al., 2004). 260 
To our knowledge there are no reports of TH sulfation or studies of sulfotransferase 261 
expression specifically in human brain endothelium.  262 
3.1.3 Proposed model for TH passage across BBB 263 
The current proposed model for thyroid hormone crossing the BBB suggests that TH 264 
is taken up primarily through MCT8 in brain endothelial cells (Fig.2).  From the 265 
endothelial cells T4 enters astrocytic end feet, possibly via OATP1C1, where it can be 266 
locally converted to T3 by D2 and exported via an unknown transporter.   MCT8 267 
mediates T3 entry to neuronal cells where it binds thyroid receptors and regulates 268 
transcription of specific genes, or T3 may be metabolised by D3 to T2. 269 
 270 
3.2 Blood-Cerebrospinal Fluid Barrier  271 
The BCSFB is localised to a monolayer of cuboidal epithelial cells of the choroid 272 
plexus located in the lateral, third and fourth ventricles of the brain that separates 273 
blood from the cerebrospinal fluid (CSF) (Fig.2).  The choroid plexus is a villous 274 
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structure attached to the ventricular ependyma, where ependymal cells and choroid 275 
plexus epithelial cells form a continuous layer (Redzic and Segal, 2004).   The 276 
choroid plexus consists of a layer of CSF-facing epithelial cells that surround a core 277 
of fenestrated capillaries and stromal cells.  Choroid plexus epithelial cells are joined 278 
together by tight junctions, providing the barrier between circulating blood and the 279 
CSF (Redzic and Segal, 2004).  The choroid plexus is a secretory epithelium that 280 
produces 70% of CSF (Cserr, 1971) formed at a rate of ~0.4mL.min-1.g tissue-1.  The 281 
total volume of CSF in the entire human CNS amounts to 150mL, thus the CSF is 282 
replaced three-four times per day (Cserr et al., 1992). 283 
3.2.1 Thyroid hormone transporters in the BCSFB 284 
Several thyroid hormone transporters have been localised to the choroid plexus 285 
(Mayerl et al., 2012, Wirth et al., 2014). MCT8 is expressed in both apical and basal 286 
membrane of human and mouse choroid plexus epithelial cells (Friesema et al., 2012, 287 
Wirth et al., 2014). MCT8 is widely expressed in human fetal brain, including in the 288 
epithelium of the choroid plexus and ependymal cells (Chan et al., 2014).  289 
OATP1C1 is detected on both apical and basal membranes of human and rodent 290 
choroid plexus epithelial cells, with a bias towards the basal surface (Grijota-Martinez 291 
et al., 2011, Roberts et al., 2008). Expression of OATP1C1 is low in the human fetal 292 
choroid plexus compared to adults and fetal rodents (Roberts et al., 2008). Expression 293 
of MCT10 and LAT2 have also been described in human fetal choroid plexus (Chan 294 
et al., 2011, Friesema et al., 2012). 295 
3.2.2 TH metabolising enzymes in the BCSFB 296 
D2 is expressed in chicken choroid plexus (Verhoelst et al., 2004) and human fetal 297 
(13 – 20 weeks gestation) choroid plexus has the highest level of D2 activity 298 
compared to other regions of the brain  (Kester et al., 2004). Choroid plexus displays 299 
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the highest level of TH sulfotransferase activity in human fetal brain and SULT1A1 300 
protein has been localised to human fetal choroid plexus (Richard et al., 2001). Very 301 
low levels of TH sulfatase activity is present in choroid plexus suggesting that it has 302 
low capacity for recovery of sulphated THs and that they are not a major reservoir of 303 
TH in the brain (Richard et al., 2001). 304 
3.2.3 TH Distributor Proteins in the BCSFB 305 
It has been shown in many species (Cavanagh et al., 1982, Ramey and Birge, 1979) 306 
that, during the early stages of development, the brain is supported in CSF that 307 
contains significantly higher levels of protein than are found in adult.  Very high 308 
expression of both TTR mRNA and protein have been demonstrated in second 309 
trimester human fetal choroid plexus (Jacobsson, 1989) and TTR has been measured 310 
in human fetal CSF as early as 12 weeks gestation suggesting an important role in 311 
early brain development (Bell JE, 1991). There are no reports of humans that lack 312 
TTR. Human fetuses and premature infants show levels of CSF protein which are 313 
higher than those at term (Bell JE, 1991). Proteins in human fetal CSF include 314 
albumin, TTR, α-1-antitrypsin, transferrin and alphafetoprotein (Bell JE, 1991). In the 315 
CSF, 80% of T4 is bound to TTR (Chanoine et al., 1992). TTR is produced by the 316 
choroid plexus epithelial cells and is secreted apically into the CSF where it 317 
constitutes up to 20% of total CSF protein (Schreiber et al., 1990). TTR has been 318 
postulated to move T4 against the free T4 gradient between blood and CSF (Chanoine 319 
et al., 1992, Southwell et al., 1993), and assist in the distribution of thyroid hormone 320 
throughout the rat brain (Chanoine et al., 1992). If synthesis of new TTR is blocked 321 
then T4 cannot cross choroid plexus epithelial cells (Southwell et al., 1993). The 322 
movement of T4 into the CSF is dependent on the binding capacity of TTR (Chanoine 323 
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et al., 1992). If the TH binding capacity of TTR is disrupted then TH cannot cross the 324 
choroid plexus. For a recent review see (Richardson et al., 2015). 325 
From studies of TTR null mice, expression and localisation data suggests that thyroid 326 
hormone may traverse the BCSFB by entering the basal side of choroid plexus 327 
epithelial cells mediated by OATP1C1 and exiting apically into the CSF via MCT8 328 
(Richardson et al., 2015). TTR null mice have 36% T4 levels in their brain compared 329 
to wildtype mice (Palha et al., 1997). In rabbit choroid plexus epithelial cells T4 was 330 
taken up and, following treatment with brefeldin A, accumulated in the epithelial cells 331 
(Zibara et al., 2015). Brefeldin A also inhibits TTR secretion in placental cells 332 
(Landers et al., 2009). This strongly suggests that TH binds to intracellular TTR and 333 
the TTR-TH complex is exported to the CSF. 334 
3.2.4 Specialised Ependymal Cells 335 
As previously mentioned, the choroid plexus is attached to the ventricular ependyma.  336 
Ependymal cells are glial cells that lack tight junctions and instead have gap junctions 337 
allowing passage of larger solutes (Brightman and Reese, 1969) and may provide a 338 
route of entry for thyroid hormones to enter nervous tissue (neuroglia and neurons) 339 
from the CSF.  In neonatal mouse a group of specialised ependymal cells called 340 
tanycytes co-express MCT8 and D2 (Guadano-Ferraz et al., 1997, Roberts et al., 341 
2008).  MCT8 and OATP1C1 are both expressed in the tanycytes of second trimester 342 
human fetal brain however only OATP1C1 expression is detected at term (Friesema et 343 
al., 2012). Tanycytes have processes that penetrate into the hypothalamus of the brain 344 
facilitating access of thyroid hormones to hypothalamic nuclei and neurons that 345 
mediate release of thyrotrophin-releasing hormone (Bolborea and Dale, 2013) and 346 
therefore are involved in the regulation of TH secretion from the thyroid gland. 347 
3.2.5 Proposed model for TH passage across BCSFB 348 
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The current proposed route for TH across the fetal BCSFB is that TH in the 349 
bloodstream enters choroid plexus epithelial cells mainly through MCT8 (Fig.2). 350 
Internalised THs bind with intracellular TTR and the TTR-TH complex is exported 351 
through the apical choroid plexus cell membrane into the CSF.  From the CSF, TH 352 
may enter the brain through ependymal cells or tanycytes.  The large amount of bound 353 
thyroxine (TTR-T4) may be important in the distribution of thyroid hormone to other 354 
areas of the brain (Chanoine et al., 1992).  355 
 356 
4. Conclusion 357 
TH is essential for normal human fetal brain development to occur but the human 358 
fetal thyroid gland does not produce significant amounts of T4 until 18 weeks 359 
gestation. Maternal TH must cross many complex biological barriers in order to reach 360 
the developing fetal brain in an adequate and timely manner. The processes by which 361 
TH crosses the human placental and brain barriers are complex and require further 362 
study since most of our knowledge is based on animal studies. Understanding how TH 363 
crosses human biological barriers at different stages of development poses a huge but 364 
important challenge for researchers.  365 
 366 
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Figure legends 374 
Figure 1. Proposed route of TH transfer across placenta. Several transporters are 375 
capable of transporting TH across placenta including MCT8, MCT10, LAT1, LAT2, 376 
OATP1A2 and OATP4A1. However placental deiodinase 3 (D3) is expressed at high 377 
levels and can convert T4 to rT3. Placenta synthesises and secretes transthyretin 378 
(TTR) that can bind maternal TH. TTR is taken up by trophoblasts and may 379 
chaperone T4 to the fetal capillaries. 380 
 381 
Figure 2.  Proposed model of TH transfer across the Blood-Brain (BBB) and 382 
Blood-Cerebrospinal Fluid (BCSFB) Barriers 383 
BBB - Brain endothelial cells take up T4 primarily through MCT8. T4 then enters 384 
astrocytic end feet via OATP1C1, where it can be locally converted to T3 by D2 and 385 
exported via an unknown transporter.   MCT8 mediates T3 entry to neuronal cells. 386 
BCSFB - T4 in the bloodstream enters choroid plexus epithelial cells through MCT8. 387 
Internalised T4 binds with intracellular TTR and the TTR-T4 complex is exported 388 
through the apical choroid plexus cell membrane into the CSF.  From the CSF, TH 389 
may enter the brain through ependymal cells or tanycytes.  390 
 391 
 392 
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Highlights 
 
• Fetal brain requires maternal thyroid hormone for normal development 
 
• Maternal thyroid hormone must traverse complex biological barriers to 
reach fetal brain 
 
• Our understanding of biological barriers to thyroid hormone is limited 
and requires further study 
 
